Physician profile
Amy Stewart
NPI 1568992766
$488,599.11
in general payments reported to CMS, 2019-2025
36 companies · $221K in 2025
The $221K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,834 · 2022: $17K · 2023: $71K · 2024: $177K · 2025: $221K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $103K · Consulting Fee: $67K · Food and Beverage: $32K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,475 · Education: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262,969.09 |
| Travel and Lodging | $102,869.80 |
| Consulting Fee | $67,406.00 |
| Food and Beverage | $31,621.21 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,475.00 |
| Education | $794.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $169,245.72 | 2021-2025 | Tremfya, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $60,174.95 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $51,579.03 | 2023-2025 | Omvoh |
| Pfizer INC. | $46,513.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $45,363.73 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $35,198.73 | 2021-2025 | Entyvio, Gattex |
| Celltrion USA INC. | $19,040.61 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $9,554.44 | 2022-2025 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $9,107.74 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $8,261.25 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $7,778.78 | 2022-2025 | Tremfya, Stelara |
| Exact Sciences Corporation | $7,571.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eli Lilly and Company | $6,781.96 | 2024-2025 | Omvoh |
| Abbvie INC. | $3,600.05 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,765.04 | 2022-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,588.58 | 2022-2025 | |
| Ardelyx, INC. | $1,371.12 | 2022-2025 | Ibsrela |
| Regeneron Pharmaceuticals, INC. | $1,310.00 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $542.51 | 2023-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $357.36 | 2025 | |
| Boston Scientific Corporation | $256.98 | 2022-2024 | Speedband Superview Super 7 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.98 | 2023-2024 | Cyltezo |
| Amgen INC. | $224.82 | 2021-2023 | Amjevita, Avsola |
| Daiichi Sankyo INC. | $218.04 | 2022-2025 | Injectafer |
| Qol Medical, LLC | $131.43 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $123.93 | 2022-2025 | |
| Therapeuticsmd, INC. | $123.48 | 2021 | |
| Braintree Laboratories, INC. | $121.21 | 2022-2025 | Suflave, Sutab |
| Biohaven Pharmaceuticals, INC. | $112.40 | 2021 | |
| Novo Nordisk INC | $59.09 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $58.34 | 2023-2024 | Linzess |
| Evofem Biosciences, INC. | $55.77 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $51.45 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $45.79 | 2023 | |
| Sandoz INC. | $33.86 | 2023-2024 | Hyrimoz |
| Evoke Pharma, INC. | $33.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.